Effects of GABAA Receptor Modulation by AP-325 on Insulin Secretion in Patients with Type 2 Diabetes

NCT05160272 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Type2 Diabetes

Interventions

DRUG: AP-325
DRUG: Placebo matching AP-325

Sponsor

The Deutsche Diabetes Forschungsgesellschaft e.V.

Collaborators

[object Object]